Mediclinic International Plc (MDC) 2018年年度报告「LSE」.pdf

1、ANNUAL REPORT AND FINANCIAL STATEMENTSfor the year ended 31 March 2018HIGHLIGHTSSUCCEEDING IN THE TURNAROUND OF THE ABU DHABI BUSINESSwith continued strong performance in Southern Africa and Dubai740 000+INPATIENT ADMISSIONSacross all operating divisions as the demand for quality healthcare services

2、 continues to increase245M SIGNIFICANT ONGOING CAPEX INVESTMENT across the Group supporting patient experience,clinical excellence,maintenance,upgrades and expansionREVENUE UP 4%to 2 870m;up 3%in constant currency termsADJUSTED EBITDA UP 3%to 515m;flat in constant currencyEARNINGS LOSS OF 492M impac

3、ted by non-cash Hirslanden and Spire impairment charges and other exceptional items ADJUSTED EARNINGS PER SHARE UP 1%to 30.0 penceTOTAL DIVIDEND FOR THE YEAR 7.90 PENCEThe Group uses adjusted income statement reporting as non-IFRS measures in evaluating performance.Refer to the Financial Review on p

4、age 29 for an explanation.CONTENTSSTRATEGIC REPORT3Report ProfileBusiness Overview4Performance Highlights 6Chairmans Statement10At a Glance12Business Model14Our Strategy,Progress and Aims18Investment Case19Five-Year SummaryPerformance and Future Outlook20Chief Executive Officers Review24Financial Re

5、view33Value Added Statement34Clinical Services OverviewRisk Management44Risk Management,Principal Risks and Uncertainties50Viability StatementDivisional Reviews52Divisional Review Switzerland56Divisional Review Southern Africa60Divisional Review UAENon-financial Performance68Sustainable Development

6、HighlightsGOVERNANCE AND REMUNERATION85Chairmans Introduction86Board of Directors90Senior Management93Corporate Governance Statement112Nomination Committee Report116Clinical Performance and Sustainability Committee Report120Audit and Risk Committee Report130Directors Remuneration Report160Statement